Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | LPL | P06858 | 1/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8641530 | 0.86 | CA2 (0.50) | SLC6A4MAOASLC6A2SLC6A3CYP3A4 | |
| SCHEMBL13940077 | 0.84 | SLC6A4 (0.45) | SLC6A4MAOASLC6A2SLC6A3LPL | |
| SCHEMBL28015145 | 0.84 | ESR1 (0.55) | SLC6A4SLC6A2SLC6A3LPLLIPG | |
| SCHEMBL21556357 | 0.82 | ESR1 (0.59) | SLC6A4SLC6A2SLC6A3LPLLIPG | |
| SCHEMBL12040851 | 0.82 | ESR1 (0.59) | SLC6A4SLC6A2SLC6A3LPLLIPG | |
| SCHEMBL19019146 | 0.82 | ESR1 (0.59) | SLC6A4SLC6A2SLC6A3LPLLIPG | |
| SCHEMBL943259 | 0.82 | LPL (0.48) | LPLLIPGGAA | |
| SCHEMBL577213 | 0.82 | LPL (0.48) | SLC6A4LPLLIPGCYP3A4 | |
| SCHEMBL142480 | 0.81 | LPL (0.62) | SLC6A4SLC6A2SLC6A3LPLLIPG | |
| SCHEMBL20245263 | 0.80 | SLC6A4 (0.50) | SLC6A4MAOASLC6A2SLC6A3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11739080-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | FORESEE PHARMACEUTICALS USA, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-3851446-A1 | PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND | Nagase & Co., Ltd. (JP) | 2021-07-21 | — | — | EP | disclosed |
| CN-106967037-B | Compound and colored curable resin composition | 东友精细化工有限公司 | 2019-12-03 | — | — | CN | disclosed |
| US-20190352288-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS CO., LTD (TW) | 2019-11-21 | — | — | US | disclosed |
| CN-106019868-B | Electrophtography photosensor | 柯尼卡美能达株式会社 | 2019-11-08 | — | — | CN | disclosed |
| CN-110402258-A | Actinic-radiation curable composition, solidfied material and film | DAINIPPON INK & CHEMICALS | 2019-11-01 | — | — | CN | disclosed |
| CN-107001067-B | Method for producing inorganic fine particle dispersion, curable composition containing the dispersion, and cured product thereof | DIC株式会社 | 2019-09-20 | — | — | CN | disclosed |
| CN-107406530-B | Solidification compound and its solidfied material and optical component | DIC株式会社 | 2019-08-20 | — | — | CN | disclosed |
| CN-104350422-B | Colored photosensitive resin composition | 住友化学株式会社 | 2019-05-17 | — | — | CN | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| EP-1304325-A1 | 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-0206741-B1 | LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1991-04-10 | — | — | EP | disclosed |
| EP-0044711-B1 | 9,11-METHANO-13-AZA-11A-CARBATHROMBANOIC ACID ANALOGUES AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-03-14 | — | — | EP | disclosed |
| US-4389413-A | 9,11-Methano-13-aza-11a-carbathrombanoic acid analogues | ONO PHARMACEUTICAL CO. LTD. (JP) | 1983-06-21 | — | — | US | disclosed |
| EP-0044711-A1 | 9,11-Methano-13-aza-11a-carbathrombanoic acid analogues and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-01-27 | — | — | EP | disclosed |
| US-4165316-A | Process for preparing sulfinyl chlorides from penicillin sulfoxides | ELI LILLY AND COMPANY (US) | 1979-08-21 | — | — | US | disclosed |
| US-4165315-A | CHLORINATION WITH AN N-CHLORO HALOGENATING AGENT | ELI LILLY AND COMPANY (US) | 1979-08-21 | — | — | US | disclosed |
| US-4081440-A | Sulfinyl halides and their preparation from penicillin sulfoxides | ELI LILLY AND COMPANY (US) | 1978-03-28 | — | — | US | disclosed |
| US-4075203-A | Process for preparing a 3-exomethylenecepham sulfoxide from penicillin sulfoxides | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | SLC6A4 3767/4885MAOA 2243/4885SLC6A2 3062/4885 |
| US-11739080-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | MMP12, MMP1, MMP11 | SLC6A4 3767/4885MAOA 2243/4885SLC6A2 3062/4885 |
| US-20190352288-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | SLC6A4 3767/4885MAOA 2243/4885SLC6A2 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.